Cover ImageSALE
Market Research Report

Global H1N1 Vaccines Market 2016-2020

Published by TechNavio (Infiniti Research Ltd.) Product code 254965
Published Content info 83 Pages
Immediate Delivery Available
Price
Back to Top
Global H1N1 Vaccines Market 2016-2020
Published: June 3, 2016 Content info: 83 Pages
Description

About the H1N1 Vaccines Market

The high level of maturity in the H1N1 vaccines market has renewed the push to develop quadrivalent vaccines that address areas of the market with unmet medical needs. Vaccines that prevent H1N1 have been a long-standing void in the treatment algorithm. Therefore, the introduction advanced vaccines in the next decade will likely alter the global H1N1 vaccines market landscape. Sanofi, AstraZeneca, and VaxInnate have also invested in quadrivalent vaccines, such as Sanofi's VaxiGrip, VaxInnate's VAX2012Q, and AstraZeneca's MEDI-550 vaccine, which will impact the US and Europe markets during the forecast period. Other areas of opportunity for novel entrants include vaccines with improved immune response and immunogenic infant vaccines.

Technavio's analysts forecast the global H1N1 vaccines market to grow at a CAGR of 4.17% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global H1N1 vaccines market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of vaccines used to prevent H1N1 infection. The report also considers the revenues to be generated from the sales of vaccines that are expected to be launched into the market during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global H1N1 Vaccines Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Sanofi
  • GSK
  • Astra Zeneca
  • CSL

Other Prominent Vendors

  • Abbott
  • Baxter International
  • CEL-SCI
  • Cipla
  • Crucell
  • Denka Seiken
  • Green Cross
  • Hualan Biological Engineering
  • iBio
  • Imunoloski Zavod
  • Inovio Biomedical
  • Lupin
  • Medicago USA
  • Merck
  • Mitsubishi Tanabe Pharma
  • Omnivest
  • Panacea
  • Pfizer
  • Protein Sciences
  • Serum Institute of India
  • Sinovac Biotech
  • Solvay
  • Zhejiang Tianyuan Bio-pharmaceuticals
  • Zydus Cadila

Market driver

  • Global action plan for influenza vaccines
  • For a full, detailed list, view our report

Market challenge

  • Vaccine storage and handling issues
  • For a full, detailed list, view our report

Market trend

  • Improved understanding of immunology
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents
Product Code: IRTNTR9538

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding the disease
  • Causes of H1N1 diseases
  • Signs and symptoms

PART 06: Regulatory scenario of vaccines

PART 07: WHO recommendations for H1N1 vaccines

  • Key H1N1 virus vaccines for 2014-2015 season in US
  • H1N1 virus vaccines approved in EU

PART 08: Reimbursement for influenza vaccines in US

  • The US healthcare reform
  • Reimbursement for influenza vaccines

PART 09: Reimbursement for influenza vaccines in other major countries

  • UK
  • Germany
  • Spain
  • Italy
  • France
  • Japan

PART 10: Market landscape

  • Global human vaccines market
  • Global H1N1 vaccines market
  • Five forces analysis

PART 11: Market segmentation by ROA

  • Intramuscular vaccines
  • Intranasal vaccines
  • Intradermal vaccines

PART 12: Geographical segmentation

  • Global H1N1 vaccines market by geographical segmentation 2015-2020
  • H1N1 vaccines market in Americas
  • H1N1 vaccines market in EMEA
  • H1N1 vaccines market in APAC

PART 13: Market drivers

  • Global action plan for influenza vaccines
  • Increase in R&D
  • Inclusion in NIP
  • Rise in awareness

PART 14: Impact of drivers

PART 15: Market challenges

  • Antigenic drift and shift of H1N1v virus
  • Vaccine storage and handling issues
  • Stringent regulatory guidelines
  • Emergence of local players

PART 16: Impact of drivers and challenges

PART 17: Market trends

  • Universal influenza vaccine
  • Emergence of quadrivalent vaccines
  • Increase in strategic alliances and M&A
  • Improved understanding of immunology

PART 18: Vendor landscape

  • Competitive scenario
  • Market share analysis 2015
  • Sanofi
  • GSK
  • AstraZeneca
  • CSL
  • Other prominent vendors

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Key buying criteria for H1N1 vaccines
  • Exhibit 03: Pediatric influenza vaccine price list 2015
  • Exhibit 04: Adult influenza vaccine price list 2015
  • Exhibit 05: Requirements for a BLA submission
  • Exhibit 06: Different types of development necessary to reach the vaccine licensing stage
  • Exhibit 07: Typical vaccine development process (over a period of up to 15 years and at a cost of up to $1 billion)
  • Exhibit 08: Regulatory testing of licensed vaccines
  • Exhibit 09: Comparison of US healthcare system before and after reforms
  • Exhibit 10: Coding options for diagnosis of influenza vaccines
  • Exhibit 11: Medicare (Part B) current procedural terminology (CPT) codes for influenza vaccines
  • Exhibit 12: Top 10 pharmaceutical companies based on global vaccines market revenues 2015 ($ billions)
  • Exhibit 13: Global human vaccines market 2015-2020 ($ billions)
  • Exhibit 14: Market share of H1N1 vaccines markets in global human vaccines market 2015
  • Exhibit 15: Global H1N1 vaccines market 2015-2020 ($ billions)
  • Exhibit 16: Five forces analysis
  • Exhibit 17: Global H1N1 vaccines market segmentation by ROA
  • Exhibit 18: Global H1N1 vaccines market segmentation by ROA 2015
  • Exhibit 19: Global H1N1 vaccines market by geography 2015
  • Exhibit 20: Global H1N1 vaccines market by geography 2020
  • Exhibit 21: Global H1N1 vaccines market revenue by geography 2015-2020 ($ billions)
  • Exhibit 22: Percentage share of H1N1 vaccines market by geography 2015-2020
  • Exhibit 23: Global H1N1 vaccines market: YoY revenue and growth based on geography 2015-2020 ($ billions)
  • Exhibit 24: H1N1 vaccines market in Americas 2015-2020 ($ billions)
  • Exhibit 25: H1N1 vaccines market in EMEA 2015-2020 ($ millions)
  • Exhibit 26: H1N1 vaccines market in APAC 2015-2020 ($ millions)
  • Exhibit 27: A few pipeline molecules for H1N1 vaccines
  • Exhibit 28: Impact of drivers
  • Exhibit 29: A typical cold chain process
  • Exhibit 30: Impact of drivers and challenges
  • Exhibit 31: Overview of major H1N1 vaccine-related acquisitions 2005-2012)
  • Exhibit 32: Market share analysis of global H1N1 vaccines market 2015
  • Exhibit 33: Sanofi: YoY revenue growth of influenza vaccines 2013-2015 ($ billions)
  • Exhibit 34: Sanofi: Geographic segmentation of influenza vaccines 2015
  • Exhibit 35: Sanofi: Key takeaways
  • Exhibit 36: GSK: YoY revenue and growth rate of Fluarix and FluLaval 2013-2015 ($ millions)
  • Exhibit 37: GSK: Geographical segmentation of Fluarix and FluLaval 2015
  • Exhibit 38: GSK: Key takeaways
  • Exhibit 39: AstraZeneca: YoY revenue and growth rate of Fluenz 2013-2015 ($ millions)
  • Exhibit 40: AstraZeneca: Geographical segmentation of Fluenz 2015 ($ millions)
  • Exhibit 41: AstraZeneca: Key takeaways
  • Exhibit 42: CSL: YoY revenue and growth rate of influenza vaccines 2013-2015 ($ millions)
  • Exhibit 43: CSL: Key takeaways
Back to Top